Skip to content

Price / book at other companies

Guardant Health logo
Guardant HealthGH
36.8×
Natera, Inc. logo
Natera, Inc.NTRA
16×+0.6×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
2.5×+1.5×
Veracyte logo
VeracyteVCYT
1.9×0.0×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
3.4×+1.0×
GeneDx Holdings logo
GeneDx HoldingsWGS

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity-0.2×
Current ratio3.4×+0.4×

Where this comes from

Calculated from Adaptive Biotechnologies’s reported figures.

Based on the most recent quarter.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's price / book?
Adaptive Biotechnologies (ADPT) reported price / book of 9.9× in Q1 2026.
How has Adaptive Biotechnologies's price / book changed year-over-year?
Adaptive Biotechnologies's price / book increased by 70.4% year-over-year, from 5.8× to 9.9×.
What is the long-term trend for Adaptive Biotechnologies's price / book?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's price / book has grown at a 0.2% compound annual growth rate (CAGR), from 11.2× to 11.3×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.